MA33747B1 - Anticorps monoclonaux diriges contre la progastrine et leurs utilisations - Google Patents

Anticorps monoclonaux diriges contre la progastrine et leurs utilisations

Info

Publication number
MA33747B1
MA33747B1 MA34864A MA34864A MA33747B1 MA 33747 B1 MA33747 B1 MA 33747B1 MA 34864 A MA34864 A MA 34864A MA 34864 A MA34864 A MA 34864A MA 33747 B1 MA33747 B1 MA 33747B1
Authority
MA
Morocco
Prior art keywords
monoclonal antibodies
antibodies against
methods
progastrin
gastrin
Prior art date
Application number
MA34864A
Other languages
Arabic (ar)
English (en)
Inventor
Julie Pannequin
Laure Boudier
Dominique Joubert
Frédéric Hollande
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Biorealites
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33747(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Biorealites filed Critical Inst Nat Sante Rech Med
Publication of MA33747B1 publication Critical patent/MA33747B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux contre la progastrine, des fragments de ceux-ci, des compositions comprenant les anticorps monoclonaux contre la progastrine, et des procédés de fabrication et d'utilisation d'anticorps monoclonaux contre la progastrine ainsi que des compositions les contenant. La présente invention concerne des procédés de traitement du cancer colorectal avec des anticorps monoclonaux contre la progastrine et des compositions comprenant des anticorps monoclonaux contre la progastrine ou des fragments de ceux-ci. La présente invention concerne en outre des procédés comprenant la détection de la progastrine, y compris des procédés de diagnostic du cancer colorectal et des procédés de surveillance de l'efficacité d'une thérapie anticancéreuse chez des sujets souffrant du cancer colorectal.
MA34864A 2009-10-16 2012-05-11 Anticorps monoclonaux diriges contre la progastrine et leurs utilisations MA33747B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
PCT/EP2010/006329 WO2011045080A2 (fr) 2009-10-16 2010-10-15 Anticorps monoclonaux contre la progastrine et leurs utilisations

Publications (1)

Publication Number Publication Date
MA33747B1 true MA33747B1 (fr) 2012-11-01

Family

ID=43086711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34864A MA33747B1 (fr) 2009-10-16 2012-05-11 Anticorps monoclonaux diriges contre la progastrine et leurs utilisations

Country Status (41)

Country Link
US (7) US9611320B2 (fr)
EP (2) EP2488551B1 (fr)
JP (3) JP5985987B2 (fr)
KR (2) KR101640520B1 (fr)
CN (2) CN104628857A (fr)
AP (1) AP2012006262A0 (fr)
AR (1) AR078659A1 (fr)
AU (1) AU2010306119A1 (fr)
BR (1) BR112012008818B1 (fr)
CA (1) CA2777691C (fr)
CL (1) CL2012000914A1 (fr)
CR (1) CR20120184A (fr)
CU (1) CU24196B1 (fr)
CY (1) CY1120913T1 (fr)
DK (1) DK2488551T3 (fr)
EA (2) EA201791876A1 (fr)
EC (1) ECSP12011796A (fr)
ES (2) ES2973217T3 (fr)
GE (1) GEP201706604B (fr)
GT (1) GT201200114A (fr)
HK (1) HK1178183A1 (fr)
HN (1) HN2012000708A (fr)
HR (1) HRP20181645T1 (fr)
IL (2) IL219019B (fr)
IN (1) IN2012DN03348A (fr)
LT (1) LT2488551T (fr)
MA (1) MA33747B1 (fr)
MX (1) MX351635B (fr)
NI (1) NI201200054A (fr)
NZ (2) NZ701709A (fr)
PE (1) PE20121649A1 (fr)
PL (2) PL3421493T3 (fr)
PT (1) PT2488551T (fr)
RS (1) RS57966B1 (fr)
SG (1) SG10201704933PA (fr)
SI (1) SI2488551T1 (fr)
TN (1) TN2012000159A1 (fr)
TW (1) TWI537002B (fr)
UA (1) UA106771C2 (fr)
WO (1) WO2011045080A2 (fr)
ZA (1) ZA201202642B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
AR078659A1 (es) * 2009-10-16 2011-11-23 Biorealites S A Anticuerpos monoclonales contra progastrina humana y sus usos
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
JP5829672B2 (ja) * 2010-03-24 2015-12-09 レ ラボラトワール セルヴィエ 結腸直腸及び胃腸癌の予防
EA028515B1 (ru) * 2010-07-26 2017-11-30 Ле Лаборатуар Сервье Способы и композиции для терапии рака печени
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (fr) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour prédire le risque de développer une néoplasie du côlon
WO2015003114A1 (fr) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Anticorps monoclonal neutralisant la protéine mic soluble pour le traitement du cancer
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
JP6740135B2 (ja) * 2014-04-18 2020-08-12 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク ヒト化抗−ｔｆ−抗原抗体
WO2016066671A1 (fr) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour traiter des cancers résistants à l'aide d'inhibiteurs de la progastrine
AU2016324021A1 (en) * 2015-09-15 2018-04-12 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
CN108780091A (zh) * 2015-12-31 2018-11-09 普莱戈斯瑞恩癌症有限责任公司 用于检测和治疗卵巢癌的组合物和方法
AU2017204685B2 (en) * 2015-12-31 2022-10-13 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating gastric cancer
MA43550A (fr) * 2015-12-31 2018-11-07 Syncerus S A R L Compositions et procédés d'évaluation du risque d'apparition d'un cancer
WO2018178364A1 (fr) * 2017-03-30 2018-10-04 Progastrine Et Cancers S.À R.L. Compositions et méthodes de traitement du cancer du poumon
EP3601347B1 (fr) * 2017-03-30 2021-11-03 Progastrine et Cancers S.à r.l. Compositions et procédés pour détecter et traiter le cancer de la prostate utilisant une molécule de liaison à la progastrine
EP3720879B1 (fr) * 2017-12-05 2022-05-11 Progastrine et Cancers S.à r.l. Thérapie de combinaison comprenant des anticorps anti-prostaglandine et immunothérapie pour traiter cancer
TW201927343A (zh) 2017-12-08 2019-07-16 瑞士商Ｅｃｓ生物識別系統有限公司 癌症診斷中之經放射標記的前胃泌激素
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
WO2019166499A1 (fr) * 2018-02-27 2019-09-06 Ecs-Progastrin Sa Progastrine en tant que biomarqueur pour l'immunothérapie
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN116143920A (zh) * 2022-12-30 2023-05-23 南京岚煜生物科技有限公司 胃泌素17的单克隆抗体及其细胞株的制备方法和应用
CN117567611B (zh) * 2023-11-22 2024-05-14 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0463151B1 (fr) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP2567974A3 (fr) * 2004-09-22 2013-05-22 Cancer Advances, Inc., Anticorps monoclonaux contre la progastrine
ES2727306T3 (es) * 2006-05-22 2019-10-15 Inst Nat Sante Rech Med Inhibidores de progastrina en el tratamiento del cáncer de colon
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
EP2337795A2 (fr) * 2008-10-01 2011-06-29 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
AR078659A1 (es) * 2009-10-16 2011-11-23 Biorealites S A Anticuerpos monoclonales contra progastrina humana y sus usos

Also Published As

Publication number Publication date
MX351635B (es) 2017-10-23
TN2012000159A1 (en) 2013-12-12
CY1120913T1 (el) 2019-12-11
WO2011045080A2 (fr) 2011-04-21
GEP201706604B (en) 2017-01-25
IL254004B2 (en) 2023-06-01
CU20120060A7 (es) 2013-04-19
KR20120091221A (ko) 2012-08-17
US11299542B2 (en) 2022-04-12
US10385125B2 (en) 2019-08-20
CU24196B1 (es) 2016-09-30
EP3421493B1 (fr) 2024-01-17
MX2012004400A (es) 2012-06-27
NZ599971A (en) 2014-12-24
EA201791876A1 (ru) 2018-01-31
PT2488551T (pt) 2018-10-31
US20180022802A1 (en) 2018-01-25
EP2488551A2 (fr) 2012-08-22
RS57966B1 (sr) 2019-01-31
CL2012000914A1 (es) 2012-09-14
AU2010306119A1 (en) 2012-05-03
GT201200114A (es) 2014-08-11
WO2011045080A3 (fr) 2011-07-07
KR20150082672A (ko) 2015-07-15
CN102791735A (zh) 2012-11-21
ES2973217T3 (es) 2024-06-19
EA029271B1 (ru) 2018-03-30
CR20120184A (es) 2012-08-20
IL219019A0 (en) 2012-06-28
BR112012008818A2 (pt) 2018-05-22
JP5985987B2 (ja) 2016-09-06
CA2777691A1 (fr) 2011-04-21
UA106771C2 (uk) 2014-10-10
US10377821B2 (en) 2019-08-13
NI201200054A (es) 2012-08-20
PE20121649A1 (es) 2012-12-08
ZA201202642B (en) 2013-06-26
NZ701709A (en) 2016-06-24
US20170306011A1 (en) 2017-10-26
JP2017212992A (ja) 2017-12-07
LT2488551T (lt) 2018-10-25
KR101640520B1 (ko) 2016-07-19
IL219019B (en) 2019-05-30
PL2488551T3 (pl) 2019-01-31
IN2012DN03348A (fr) 2015-10-23
JP2015145380A (ja) 2015-08-13
EP3421493C0 (fr) 2024-01-17
HN2012000708A (es) 2015-06-22
EP2488551B1 (fr) 2018-07-25
ECSP12011796A (es) 2012-06-29
US20220195035A1 (en) 2022-06-23
US20110117086A1 (en) 2011-05-19
HK1178183A1 (zh) 2013-09-06
EP3421493A1 (fr) 2019-01-02
CA2777691C (fr) 2018-02-27
DK2488551T3 (en) 2018-10-08
US20170174761A1 (en) 2017-06-22
US20170306012A1 (en) 2017-10-26
SG10201704933PA (en) 2017-07-28
US9611320B2 (en) 2017-04-04
PL3421493T3 (pl) 2024-04-29
IL254004A0 (en) 2017-10-31
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
HRP20181645T1 (hr) 2018-12-14
CN104628857A (zh) 2015-05-20
BR112012008818B1 (pt) 2021-10-19
TWI537002B (zh) 2016-06-11
JP6272793B2 (ja) 2018-01-31
ES2690943T3 (es) 2018-11-23
US20200002413A1 (en) 2020-01-02
JP2013507138A (ja) 2013-03-04
SI2488551T1 (sl) 2019-01-31
US10385124B2 (en) 2019-08-20
AP2012006262A0 (en) 2012-06-30
EA201200597A1 (ru) 2012-12-28
US10385126B2 (en) 2019-08-20
TW201119675A (en) 2011-06-16

Similar Documents

Publication Publication Date Title
MA33747B1 (fr) Anticorps monoclonaux diriges contre la progastrine et leurs utilisations
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
EP4357783A3 (fr) Système et procédés hautement sensibles pour l'analyse de troponine
WO2010056337A3 (fr) Procédés et systèmes d'utilisation d'exosomes pour déterminer des phénotypes
MA32561B1 (fr) Anticorps neutralisant le cytomegalovirus humain et leurs utilisations
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
WO2007035651A3 (fr) Bio-essai de diagnostic du lupus erythemateux systemique
WO2010027903A3 (fr) Diagnostic du cancer du poumon
WO2011015602A3 (fr) Biomarqueurs du cancer du poumon
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
WO2011047033A3 (fr) Biomarqueur d'identification de cellules tumorales de mélanome
EP2566983A4 (fr) Analyse en série de biomarqueurs à des fins de diagnostic d'une maladie
EP1934377A4 (fr) Procédés et compositions permettant d'identifier des biomarqueurs utiles au diagnostic et/ou au traitement d'états biologiques
ATE548050T1 (de) Diagnoseverfahren
MA30393B1 (fr) Procede de traitement, de diagnostic ou de detection du cancer
WO2007084397A3 (fr) Méthode de traitement de slpi par chymase
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2009010751A (es) Composiciones y metodos de deteccion.
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
WO2010031749A9 (fr) Compositions et procédés pour détecter tlr3
WO2010044506A3 (fr) Anticorps humain spécifique de tmprss4
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
WO2007019276A3 (fr) Detection quantitative de plomb dans de l'eau
BR112015021507A2 (pt) métodos e composições para o diagnóstico de pré-eclampsia
NZ601643A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure